Pharming Group N.V annual revenue
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Revenue Growth & History (PHAR)
Pharming Group N.V reported $376.1M in revenue for fiscal 2025, an increase of 26.56% from the previous fiscal year.
View full Pharming Group N.V company overviewPharming Group N.V annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $376.1M | $78.9M | +26.56% |
| 2024 | 2024-12-31 | $297.2M | $51.9M | +21.15% |
| 2023 | 2023-12-31 | $245.3M | $39.7M | +19.30% |
| 2022 | 2022-12-31 | $205.6M | $6.8M | +3.39% |
| 2021 | 2021-12-31 | $198.9M | −$13.3M | −6.27% |
| 2020 | 2020-12-31 | $212.2M | $22.8M | +12.03% |
| 2019 | 2019-12-31 | $189.4M | — | — |
Pharming Group N.V quarterly revenue
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $90.2M | −$3.0M | −3.23% |
| Q1 2026 | 2026-03-31 | $72.4M | — | — |
| Q4 2025 | 2025-12-31 | $106.5M | — | — |
| Q3 2025 | 2025-09-30 | $97.3M | — | — |
| Q2 2025 | 2025-06-30 | $93.2M | — | — |
Pharming Group N.V revenue growth trends
Over the last five reported fiscal years, revenue grew from $212.2M to $376.1M, a compound annual growth rate of 12.13%. Pharming Group N.V's latest reported quarter, Q2 2026, generated $90.2M in revenue, a decrease of 3.23% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Pharming Group N.V source filings ↗Community posts
Pharming secures priority review for lower-dose pediatric Joenja
Pharming ($PHAR) said the FDA accepted its supplemental application for a lower-dose Joenja formulation and granted priority review. The proposed expansion addresses patients aged four and older with activated PI3K delta syndrome who weigh ...
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...
